Curcumin-based magnetic nanostructured system for dual response of imaging and therapeutics

Patent metadata

Field	Value
Publication number	US-2020038525-A1
Application number	US-201816055221-A
Country	US
Kind code	A1
Filing date	Aug 6, 2018
Priority date	Aug 6, 2018
Publication date	Feb 6, 2020
Grant date	—

Abstract

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

First claim

1 . A composition comprising:
a platform of nanoporous structured silica selected from the group consisting of SiSBA-16, Q-10 silica, mesocellular foam, silicalite, mesosilicalite, SiKIT-6, ULPFDU-12 or SiMCM-41, high silica zeolites based on ZSM-5, Beta, USY, Mordenite, ZSM-11, ZSM-12, ZSM-22, ZSM-23, mesocarbon, graphene oxide and mixtures thereof, superparamagnetic iron oxide nanoparticles (“SPIONS”) in an amount ranging from about 5 wt % to about 30 wt % based on total weight of the composition, and at least one curcuminoid through equilibrium or enforced adsorption technique.

2 . The composition of claim 1 , wherein the platform of nanoporous structured silica comprises MSU-foam.

3 . The composition of claim 1 , wherein the platform of nanoporous structured silica comprises SiSBA-16.

4 . The composition of claim 1 , wherein the platform of nanoporous structured silica comprises Q-10.

5 . The composition of claim 1 , wherein the SPIONs comprise Fe 2 O 3 or a mixture of NiFe 2 O 4 , CuFe 2 O 4 , MnFe 2 O 4 or CoFe 2 O 4 .

6 . The composition of claim 1 , wherein the SPIONs comprise γ-Fe 2 O 3 .

7 . The composition of claim 1 , wherein the SPIONs have an average particle size ranging from about 7 to about 18 nm when the platform of nanoporous structured silica is MSU-foam; about 9 to 21 nm when the platform of nanoporous structured silica is SiSBA-16; or about 10 to about 25 nm when the platform of nanoporous structured silica is Q-10.

8 . The composition of claim 1 , wherein the curcuminoid is loaded in an amount ranging from 50 to 70 wt %.

9 . The composition of claim 1 , further comprising a polymer, wherein the SPIONs and/or the curcuminoid is covered with or incorporated into a polymer; and/or wherein one or more components of the composition is functionalized with chitosan, polyacrylic acid, PLGA, or another agent to increase its biocompatibility in vivo.

10 . The composition of claim 1 , further comprising at least one antibody or other targeting agent that binds to various types of cancer, neoplasm, or tumor cells.

11 . The composition of claim 1 that has a degree of magnetization (M, emu/g) as measured by vibrating sample magnetometry (VSM) greater than an otherwise identical composition wherein the platform of nanoporous structured silica consists of SiSBA-16, Q-10 silica, mesocellular foam, silicalite, mesosilicalite, SiKIT-6, ULPFDU-12 or SiMCM-41.

12 . The composition of claim 1 that has a percentage of cumulative curcuminoid release, in phosphate buffered saline (PBS) at pH 5.6 and 37° C. over 72 hours, greater than an otherwise identical composition wherein the platform of nanoporous structured silica consists of SiSBA-16, Q-10 silica, mesocellular foam, silicalite, mesosilicalite, SiKIT-6, ULPFDU-12 or SiMCM-41.

13 . A method for treating a cancer, neoplasm, or tumor comprising administering the composition of claim 1 to a subject in need thereof.

14 . The method of claim 13 , wherein the composition is administered parenterally.

15 . The method of claim 13 , wherein the composition is administered in situ into or around a cancer, neoplasm, or tumor.

16 . The method of claim 13 , wherein the composition is externally magnetically guided to, or magnetically localized in, a target in the body of the subject after administration.

17 . The method of claim 13 , further comprising inducing hyperthermia in cells or tissues to which the SPIONs have bound or otherwise localized.

18 . A method for detecting cancer, neoplasm, or tumor cells comprising:
administering the composition of claim 1 that contains at least one agent that binds to or otherwise targets cancer, neoplasm, or tumor cells to a subject suspected of having a cancer, neoplasm, or tumor, detecting the SPIONs using nuclear magnetic resonance (NMR) or X-ray imaging, selecting a subject in which the SPIONs display an abnormal accumulation, localization or distribution compared to a control subject not having a cancer, neoplasm, or tumor; and treating the selected subject for the cancer, neoplasm, or tumor.

19 . A method for making the composition of claim 1 comprising:
impregnating nanostructured pore surfaces of the platform of nanoporous structured silica with SPIONs,
calcining the impregnated platform of structured silica between 500 and 900° C., and
adsorbing the curcuminoid onto the calcined platform of structure silica and magnetic nanoparticles.

20 . The method of claim 19 , wherein the platform of nanoporous structured silica is at least one of MSU-foam, SiSBA-16, or Q-10; and the curcuminoid is curcumin which is adsorbed through an equilibrium or enforced adsorption technique.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya

Classifications

• A61K47/6929

  the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/12 Primary

  Ketones · CPC title

• A61K47/6923

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title